Stratta R J, Taylor R J, Ozaki C F, Bynon J S, Miller S A, Baker T L, Lykke C, Krobot M E, Langnas A N, Shaw B W
Department of Surgery, University of Nebraska Medical Center, Bishop Clarkson Memorial Hospital, Omaha 68198-3280.
Surg Gynecol Obstet. 1993 Aug;177(2):163-71.
Currently, diabetes mellitus is the most common cause of renal failure in adults. However, combined pancreatic and renal transplantation (PRT) remains controversial when compared with renal transplantation alone (RTA) in diabetic recipients. We analyzed the results and morbidity in four age-matched groups--31 patients with Type I diabetes undergoing PRT before dialysis, 30 patients with diabetes who are dependent of dialysis undergoing PRT, 31 concurrent and historic patients with Type I diabetes undergoing RTA and 31 concurrent patients without diabetes undergoing RTA. All patients received cadaver donor organs and were managed with cyclosporine and prednisone immunosuppression with selective OKT3 induction. The four groups were comparable with respect to age, weight, gender, duration and severity of diabetes, dialysis type, number of retransplants, degree of sensitization, preservation time and matching. The groups differed with regard to duration of dialysis and period of follow-up evaluation, pretransplant blood transfusions, racial distribution and OKT3 induction therapy. PRT was associated with a greater morbidity rate as evidenced by a slightly higher incidence of rejection, infections and reoperations. The number of readmissions and hospitalization period during the first 12 months was also greater after PRT versus RTA. However, none of these differences were significant. No detrimental effect was noted on renal allograft function at one year; patient and graft survival was actually higher in the PRT groups. Quality of life was improved in nearly 90 percent of PRT recipients. Although the improved results after PRT may be attributed to selection bias, only lesser differences were noted among the four study groups. The aforementioned data suggest that appropriate patient selection can overcome the morbidity associated with PRT, resulting in excellent patient and graft survival with the potential for complete rehabilitation.
目前,糖尿病是成人肾衰竭最常见的病因。然而,与单纯肾移植(RTA)相比,糖尿病受者接受胰肾联合移植(PRT)仍存在争议。我们分析了四个年龄匹配组的结果和发病率——31例I型糖尿病患者在透析前接受PRT,30例依赖透析的糖尿病患者接受PRT,31例同期及既往的I型糖尿病患者接受RTA,以及31例同期无糖尿病患者接受RTA。所有患者均接受尸体供体器官,并采用环孢素和泼尼松免疫抑制,选择性使用OKT3诱导治疗。四组在年龄、体重、性别、糖尿病病程和严重程度、透析类型、再次移植次数、致敏程度、保存时间和配型方面具有可比性。四组在透析时间、随访评估时间、移植前输血情况、种族分布和OKT3诱导治疗方面存在差异。PRT的发病率较高,表现为排斥反应、感染和再次手术的发生率略高。与RTA相比,PRT后前12个月的再入院次数和住院时间也更多。然而,这些差异均无统计学意义。术后一年未发现对肾移植功能有不利影响;PRT组的患者和移植物存活率实际上更高。近90%的PRT受者生活质量得到改善。尽管PRT后结果的改善可能归因于选择偏倚,但在四个研究组中仅发现较小差异。上述数据表明,合适的患者选择可以克服与PRT相关的发病率,从而实现出色的患者和移植物存活率,并有可能实现完全康复。